Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (156)	2/17/1999 1:42:00 PM
From: Biomaven	Respond to of 3158

jeffrey, I prefaced my remark with "assuming the drugs were approved today." If these two drugs were on the market today and performed in humans anything like they performed in mice, I guarantee that ENMD would have a market cap well north of $800m, even without the hype. We don't really know anything much about the GZMO license. My reading of the ENMD/CH agreement is that ENMD had at least the right of first negotiation, if not first refusal, so it is possible that ENMD passed on this molecule. Although GENZ has lots of resources, it's not at all clear if this also applies to its progeny - GZTC had to have recourse to a floorless convertible last year. GZMO is an interesting speculation, and was definitely oversold. I own a smidge I picked up when the deal with CH was first announced, but haven't really studied it closely. Peter